一种RNA干扰疗法有可能实现慢性乙型肝炎病毒感染的功能治愈
Ze-Ao Huang1,2, Yang Yang1, Shuo Yang1
1Beijing Youcare Kechuang Pharmaceutical Technology Co. Ltd., Kechuang 7th Street, BDA, Beijing, 100176, China.
Nature communications
|December 1, 2025
概括
一种新的小干扰RNA (siRNA),KC13-M2G2,有效地抑制乙型肝炎表面抗原 (HBsAg),并在临床前模型中恢复宿主免疫力. 这种强效的药物显示出在慢性乙型肝炎病毒 (HBV) 感染中具有功能治愈的前景.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 病毒学 病毒学
- 在RNA疗法方面.
背景情况:
- 慢性乙型肝炎病毒 (HBV) 感染是一个全球性的健康问题.
- 目前的治疗方法受限于由于B型肝炎表面抗原 (HBsAg) 水平高而导致的免疫衰竭.
- 需要新的治疗方法来恢复宿主免疫功能.
研究的目的:
- 开发和评估一种针对HBV S区域的新型小干扰RNA (siRNA) 剂.
- 评估siRNA剂在抑制HBsAg和恢复宿主免疫力的有效性.
- 将新型siRNA药物的疗效和安全性与现有的临床选择进行比较.
主要方法:
- 开发一种针对HBV S区域的siRNA (KC13-M2G2).
- 在体外对所有HBV基因型进行抗病毒疗效测试.
- 在多个小鼠模型中进行体内研究,以评估HBsAg和HBVDNA减少和抗体血清转化.
- 在Sprague-Dawley大鼠和Cynomolgus子中进行毒性研究.
主要成果:
- KC13-M2G2在所有HBV基因型中表现出强大的体外抗病毒活性.
- 在体内研究显示,KC13-M2G2.2.与HBsAg和HBVDNA的快速和持续的减少.
- KC13-M2G2诱导了乙型肝炎表面抗体血清转化,表现优于elebsiran和bepirovirsen.
- 在动物和非人类灵长类动物的毒性研究中观察到令人满意的生物安全概况.
结论:
- KC13-M2G2是一种强大的HBV S区域向siRNA,具有显著的功能治愈潜力.
- 该药物有效抑制HBsAg,恢复宿主免疫反应,并显示出有利的安全性.
- 预计KC13-M2G2在临床环境中将超过目前的治疗方法,如elebsiran和bepirovirsen.
更多相关视频
11:34A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
2.6K
05:55Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System
Published on: December 21, 2019
7.1K
相关概念视频
Retrovirus Life Cycles
49.2K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
49.2K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Viruses with RNA Genomes
751
RNA viruses are categorized into positive-strand, negative-strand, or double-stranded groups based on their genomic structure and replication mechanisms. This classification dictates how they exploit host cellular machinery for protein synthesis and replication. Some RNA viruses also utilize reverse transcription as part of their life cycle, further diversifying their replication strategies.Positive-Strand RNA VirusesPositive-strand RNA viruses have genomes that function directly as messenger...
751
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
457
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
457
siRNA - Small Interfering RNAs
18.3K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
18.3K
